DRMAW
Dermata Therapeutics Inc. WarrantKey Statistics
About Dermata Therapeutics Inc. Warrant
Dermata Therapeutics Inc. (DRMAW) is a pioneering biotechnology firm focused on harnessing advanced therapeutics to address pressing dermatological conditions, particularly acne, which presents significant unmet medical needs. The company utilizes its proprietary technology platform to develop a robust pipeline of innovative product candidates aimed at providing effective solutions for skin disorders. With a strong commitment to innovation and a strategic foothold in the biotechnology sector, Dermata represents an attractive investment opportunity for institutional investors seeking exposure to transformative healthcare advancements.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.09M |
| Operating Margin | 0.00% |
| Return on Equity | -103.60% |
| Return on Assets | -52.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.59 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $3.17M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DRMAW and any ticker you trade — then tracks every position and per-strategy win rate.